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 T-cell activation is one of the key mechanisms for the generation of adaptive immunity. This 
process begins from the T-cell receptor (TCR) recognition of agonist ligand presented by antigen 
presenting cells (APC) like dendritic cells. It is known that multiple interactions between agonist ligand 
and TCR are required to activate a T-cell, while similar interactions between antagonist ligand and TCR 
would only weakly activate the T-cell. Although much is known about T-cell activation due to agonist 
and antagonist ligands, few experiments in the past have shown how T-cells react to both antagonist 
and agonist ligands at the same time; which is shown to be the case during several infections. Using a 
micropipette adhesion frequency assay multiple scenarios involving agonist and antagonist ligands can 
be simulated. Interactions that were looked at involved spatial and time differences between agonist 
and antagonist stimulation of the T-cell. For each type of ligand stimulation responses from at least 
three T cells were recorded. A one-way ANOVA or student’s t-test was used for analysis of the data for 
each stimulation type. Results from the experiments using local with simultaneous simulation and global 
stimulation proved to be significant when agonist stimulation only and agonist plus antagonist 
stimulation were compared, however the results from local and time delayed experiment proved to be 
insignificant. Both local with simultaneous presentation and global stimulation showed how the addition 
of antagonist stimulation can cause the T-cell exhibit a higher adhesion frequency to agonist ligand, 
especially with contact times under one second. When we planned those experiments we expected that 
antagonist ligands inhibition of agonist stimulation would be seen as effect opposite to the one 
observed. We expected to see the lowering of the adhesion frequency . However, local and time-delay 
stimulation showed a more complex behavior of T-cells in their reaction to stimulus. In the future with 
knowledge of these interactions it will be possible to focus in on the exact mechanism of T-cell 
activation modulation by antagonist ligands. 
Introduction 
The purpose of my research at Dr. Zhu’s Cellular and Molecular Biomechanics Laboratory at 
Georgia Institute of Technology was to look into how antagonist and agonist peptides complexed with 
major histocombatibility complexes (pMHCs) interacted with the T-cell to inhibit or expedite its 
activation. A T-cell can be activated by the presentation of agonist pMHC on the surface of an antigen 
presenting cell (APC) binding to the T-cell receptor complex (TCR) a number of times great enough to 
initiate intra cellular signaling. The amount of pMHCs needed to activate a T-cell depends on the quality 
of the peptide and its affinity for TCR. Despite the fact that only agonist pMHC is needed to activate the 
T-cell, in normal biological scenarios agonist pMHCs are not the only pMHCS present on the APC. 
Antagonist pMHCS, ones that bind to a receptor cause weak modified cellular response, are often 
present in the body during infection. However, there have been few studies that look at how T-cells 
react to combined stimulus of these two types of pMHCs; agonist and antagonist.     
By using adhesion frequency assays between red blood cells (RBCs) and T-cells it is possible to 
determine the extent of T-cell recognition of surface ligands coated on the red blood cell. Through a 
specific protocol of stimulation by both antagonist and agonist ligands the goal is to show how 
antagonist ligands affect T-cell recognition of agonist ligands, and thusly T-cell activation. To determine 
the global effect of antagonist ligands on T-cell activation, microbeads coated in antagonist ligand were 
presented to the T-cell at the same time as the RBC coated in agonist ligand, however in a different 
location on the T-cell.  For determining the local effect on activation, first the microbead with antagonist 
were presented for 1 minute then the RBC with agonist were presented directly after antagonist 




Preparation of Red Blood Cells and pMHCs 
RBCs were isolated from whole blood of healthy volunteers according to protocols approved by the 
Institutional Review Board of Georgia Institute of Technology. Naive CD8 OT1 T cells were generated 
according to Emory University IACUC approved protocols. Ovalbumin-derived peptides OVA, E1, and R4, 
and a vesicular stomatitis virus-derived peptide VSV were synthesized using a standard F-moc 
(9-fluorenylmethyloxycarbonyl) chemistry on a Symphony/Multiplex Peptide Synthesizer and analyzed 
by HPLC and mass spectrometry at the Chemistry Core Facility of the Department of Microbiology and 
Immunology, Emory University School of Medicine. Peptides bound to monomeric wild-type H-2Kb 
tagged with a single biotin at the C terminus were produced by the NIH Tetramer Core Facility at Emory 
University. pMHCs were stored at -80 C and a fresh aliquot was used in each experiment. To couple 
pMHC onto RBCs and beads monomeric pMHCs were coated onto RBCs or polystyrene beads by biotin–
streptavidin coupling. RBCs were biotinylated using different concentrations (to vary the pMHC density) 
of biotin-X-NHS (Calbiochem) per manufacturer’s instruction incubated with either 1mg/ml tetrameric 
wide-type streptavidin (Pierce) for 30 min at 4 C, and incubated with 20 mg/ml biotinylated pMHC 
monomers for 30 min at 4 C. Cells were washed three times after each step. The surfaces of bio-
tinylated polystyrene (6 micron diameter, Spherotech) were used as an alternate stimulus of the T-cell. 
Beads were allowed to react with streptavidine maleimide (Sigma-Aldrich) and incubated with sub 
saturating concentrations of biotinylated pMHCs for 30min at room temperature.  
 
Adhesion Frequency Assay  
This assay uses micromanipulation to precisely set up cell–cell contact with controlled area/time and 
uses an ultrasensitive force sensor to mechanically detect the presence of adhesion at the end of the 
contact. The micropipette apparatus uses a pipette to aspirate a T cell and move it in and out of the 
contact with a pMHC bearing red blood cell. The adhesion sensor in the apparatus is a pipette-aspirated 
RBC thanks to its ultrasoft membrane that enables the detection of a sub-piconewton force, an order of 
magnitude smaller than the characteristic force required to break a typical receptor ligand bond, 
thereby ensuring the detection of single bonds. In the micropipette system, pMHCs are directly coated 
on the RBC surface and adhesion is detected by visual observation of the RBC membrane deflection. The 
likelihood of adhesion is estimated from the frequency of adhesions occurred in a large number of 
contacts made under as close to identical conditions as possible. The present work estimated an 
adhesion frequency (Pa) from 50 cyclically repeated contacts of a single pair of cells and a mean Pa 
s.e.m. from several pairs of cells.  
.  
Global T-cell activation Assay Experiment 
A baseline adhesion frequency using a T cell and a RBC coated with agonist pMHCs was recorded. Then a 
glass bead coated with antagonist pMHCs was brought into contact with a different spot of the T cell by 
pressing a microbead on the T-cell, and the adhesion frequency between the RBC bearing agonist pMHC 
and the T cell was again measured. Control experiments were performed using beads coated with no 




Bead coated with 
pMHC(WT SA, WT 
VSV, WT R4, or WT E1) 
Red blood cell 





Graphs: 0.5 and 2s contact times WT OVA(agonist) on red blood cell(positive control), WT VSV(null 











WT OVA and WT R4 
bead -0.0563 0.0229 
WT OVA and WT VSV 
bead 0.0537 0.1329 
WT OVA only -0.1496 -0.0704 
 
0.5 and 2s contact times WT OVA on red blood cell(positive control), WT SA on bead(negative control), 








treatment 95% confidence interval 
WT OVA and WT R4 bead -0.0023 0.0994 
WT OVA and WT VSV bead -0.0329 0.0688 












WT OVA and WT E1 
bead -0.03 0.0407 
WT OVA and WT SA 
bead -0.0734 -0.0026 
WT OVA only -0.0787 -0.008 
 
Statistical Analysis/Results 
Samples size determined for cell adhesion experiment was based on treatment with largest number of 
cells used, which varied for each experiment. Graphs error bars represent standard deviation for each 
average adhesion frequency. Sample size for experiment using WT R4 was twelve (n=12), and for WT E1 
experiment was ten (n=10). A one-way ANOVA was used to compare significance between means, and a 
p-value less than 0.05 (p<0.05) was deemed significant. Values from one-way ANOVA were put through 
a multiple comparison test in MATLAB and means with confidence intervals containing zero were 
considered significantly different from means whose confidence intervals did not contain zero.  
Experiments using WT R4 were analyzed using one-way ANOVA and gave a p value of 1.1420x10^-7 and 
0.0748 for 0.5s and 2s contact times respectively.  This shows that only the 0.5 second contact time has 
means that are significantly different. A multiple comparison test confirmed these results with all of the 
confidence intervals for the 2 second contact time containing zero, and 0.5 second contact time showed 
the treatment of WT OVA and WT R4 bead was significantly different from both other means. 
 P-values for cell adhesion experiment using WT E1 were 0.01 for 0.5s contact time and 3.47x10^-5 for 
2s contact time, showing both graphs had a means significantly different from one another. Upon 
analysis of results using a multiple comparison test using confidence intervals WT OVA and WT E1 
treatment means were significantly different from both WT OVA only and WT OVA + WT SA bead 







WT OVA and WT E1 
bead -0.0262 0.0422 
WT OVA and WT SA 
bead -0.0962 -0.0278 
WT OVA only -0.1042 -0.0358 
Local time delayed T-cell activation Experiment 
This experiment involves a Micropipette Adhesion Frequency assay between a mouse OT1 T-cell and a 
human Red Blood Cell (RBC) covered with agonist peptide major histocombatibility complex (pMHC) 
after initial contact with a microbead(6 micrometer diameter) covered with antagonist pMHC for varying 
time periods. This was done by bringing an antagonist-bearing bead into contact with a T cell for a range 












Blue = running frequency of T-cell before antagonist stimulation with bead 





Top left picture is T-cell being 
stimulated with red blood cell coated 
with WT OVA, agonist, pMHC. Top 
right is showing bead coated with WT 
R4, antagonist, pMHC being held 
against T-cell for 1 min. Bottom left 
shows stimulation again with WT OVA 
pMHC coated red blood cell.  
Local w/o time delayed T-cell activation (simultaneous stimulation) 
This is extremely similar to the Local time delayed T-cell activation experiment; however, this 
experiment has no microbead involved. Instead the RBC is covered with mixture of antagonist and 
agonist pMHC to allow us to see what will happen when the agonist and antagonist are presented not 












Experiment  Agonist Peptide Used Antagonist Peptide 
Used 
Adhesion Frequency(0.5 seconds,  
2 seconds) 
Global stimulation WT OVA WT E1 and WT R4 WT E1 (increase, increase) 
WT R4 (increase, no change) 
Local Time-Delayed 
stimulation 




WT OVA WT R4 Increase, no change 
Although micropipette adhesion frequency assays have only been used for the past 15 years 
(Chesla et al. 1998), trends seen from these experiments can point how to interpret certain interactions 
between cells that have never been quantified. For instance in the global stimulation the antagonist 
coated bead was not always placed the same distance from the agonist contact point, nor was it in the 
same spot for different cells; however, by using this stimulation protocol it is now possible for us to 
understand how these antagonist ligands seem to not distract the cell from agonist stimulation, but 
instead enhances this interaction. This is something that could not have been inferred from previous 
experimentation on T-cells, nor could have been observed if adhesion assays had not been used.  
 Another interesting observation from these experiments was the interaction between agonist 
and antagonist ligands when both were presented to the T cell in the same place and time. This showed 
that even when agonist ligand was present in a small amount compared to antagonist ligand the T cell 
showed a large increase in the frequency of the cell recognizing this ligand. Although this result was 
expected since affinity for agonist is much higher than that of antagonist, this makes understanding the 
activation of T cells even easier due to the fact that a similar response was shown in the global 
stimulation. However in global stimulation experiments, it was in a way that shows how antagonist 
ligands seem to repel the attention of the cell away from antagonist ligand and bring the cells’ attention 
more towards agonist. Since contact times below one second showed similar reactions of increased 
adhesion frequency between these two stimulations that could prove that the road towards activation 
could be decided within the first minute of stimulation. This proves how quickly and precisely these cells 
work in recognizing antigen within the body. 
Conclusion 
 Overall these experiments showed how fast recognition of an antigen by T-cells and subsequent 
T cell activation might be in situ. Now that the time scale and type of stimulation has been narrowed 
down we can move forward in a more thorough manner to investigate how these stimulations cause the 
first step of T-cell activation. Understanding this could help immunologist study why certain diseases or 
injuries cause the type of responses within the body that can seem perplexing. Furthermore how these 
cells activate could give insight into why in some cases T-cells become activated and begin attacking 
healthy tissues in the body like in the case of autoimmune diseases like multiple sclerosis and diabetes 
type 1. Knowing the mechanism of T-cell activation is a fundamental part of our immune response and 
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